Aspheric-based procedures reduce need for re-treatments

Article

Aspheric-based treatments with the SCHWIND ESIRIS excimer laser and ORK-CAM software offer high predictability, increases in visual acuity (VA) and no induction of aberrations.

Aspheric-based treatments with the SCHWIND ESIRIS excimer laser and ORK-CAM software offer high predictability, increases in visual acuity (VA) and no induction of aberrations, according to a recent multicentre study conducted by Maria Clara Arbelaez, MD of the Muscat Eye Laser Center, Muscat, Oman and colleagues from the Charles University, Czech Republic.

The study of 183 eyes utilized the SCHWIND aberration-free treatment, which is designed to leave preoperative higher-order aberrations (HOAs) unchanged allowing patients to retain a habitual sight impression. All flaps were created using the Carriazo-Pendular microkeratome.

In 71% of eyes, the planned refractive result was achieved with a minimum deviation of ±0.25 D. Ninety-one percent were in the area of ±0.5 D and 100% of eyes achieved ±1 D.

Postoperative vision without aids compared with preoperative vision with glasses or contact lenses also increased significantly. At six-months follow-up, 86% of all eyes had achieved an uncorrected visual acuity (UCVA) of 20/20 or better, while only 69% had a best corrected visual acuity (BCVA) of 20/20 or better.

The study also demonstrated that the ORK-CAM software effectively aids the compensation of biomechanical changes of the cornea. At six-months follow-up, no growth of significant aberrations, such as coma or spherical aberration were observed.

It was concluded that the ESIRIS excimer laser and ORK-CAM software can provide good visual results as well as reducing the need for re-treatments.

Recent Videos
David Yorston, FRCS, FRCOphth, discusses his EURETINA keynote lecture
Hoda Shamsnajafabadi, MSc, PhD, presents at the 2024 EURETINA meeting
Timothy L Jackson PhD, MB ChB, FRCOphth, speaks about a combination therapy for VEGF-A/C/D inhibition with sozinibercept and ranibizumab
Carl Awh, MD, FASRS, speaks about the American Society of Retina Specialists (ASRS) at EURETINA
Stefano Mercuri, MD, first author of the winning eposter “Genotype-phenotype correlations in a cohort of genetically determined Retinitis Pigmentosa (RP) Italian patients with Rho gene mutations”
Bahram Bodaghi, MD, PHD, FEBO at the 2024 EURETINA meeting
Enrico Borrelli, MD, FEBO, speaks at EURETINA
Aleksandra Rachitskaya, MD, FASRS, speaks about the Vit-Buckle Society at the 2024 EURETINA Congress.
© 2024 MJH Life Sciences

All rights reserved.